Skip to Content

Masimo Corporation

Corporate Governance / Derivative

  • Date:
  • 3/21/2024
  • Company Name:
  • Masimo Corporation
  • Stock Symbol:
  • MASI
  • Class Period:
  • FROM 2/28/2023 TO 7/17/2023
  • Status:
  • Filed
  • Filing Date:
  • 8/22/2023
  • Court:
  • U.S. District Court: District of Southern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Masimo Corporation (NASDAQ: MASI) on behalf of long-term stockholders following a class action complaint that was filed against Masimo on August 22, 2023 with a Class Period from February 28, 2023 to July 17, 2023. Our investigation concerns whether the board of directors of Masimo have breached their fiduciary duties to the company.

According to the filed complaint, during the Class Period, Masimo and the Defendants made materially false and misleading statements and engaged in a scheme to deceive the market and a course of conduct that artificially inflated the price of Masimo’s common stock and operated as a fraud or deceit on Class Period purchasers of Masimo’s common stock by materially misleading the investing public. Later, when Masimo and Defendants’ prior misrepresentations and fraudulent conduct became apparent to the market, the price of Masimo’s common stock materially declined, as the prior artificial inflation came out of the price over time. As a result of their purchases of Masimo’s common stock during the Class Period, Plaintiff and other members of the Class suffered economic loss, i.e., damages under federal securities laws. 

Masimo’s stock price fell in response to the corrective event on July 17, 2023, as alleged supra. On July 17, 2023, Defendants disclosed information that was directly related to their prior misrepresentations and material omissions concerning Masimo’s forecasting processes and 2023 full-year financial guidance.

In particular, on July 17, 2023, Masimo reduced the lower end of full year revenue guidance for the healthcare business to $1.30 billion from $1.45 billion. The Company also announced a reduction in annual revenue guidance for the non-healthcare business to $800 million to $850 million from $965 million to $995 million.

If you are a long-term stockholder of Masimo, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Masimo Corporation. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: